Loading clinical trials...
Loading clinical trials...
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression
Conditions
Interventions
Liafensine
Placebo
Locations
45
United States
University of Alabama at Birmingham
Huntsville, Alabama, United States
Alea Research
Phoenix, Arizona, United States
Collaborative Neuroschience Research, LLC
Garden Grove, California, United States
Behavioral Research Specialists, LLC
Glendale, California, United States
Sunwise Clinical Research, LLC.
Lafayette, California, United States
Excell Research
Oceanside, California, United States
Start Date
June 29, 2022
Primary Completion Date
February 6, 2024
Completion Date
March 5, 2024
Last Updated
May 15, 2025
NCT06731621
NCT04480918
NCT04041479
NCT06524830
NCT03320304
NCT06895863
Lead Sponsor
Denovo Biopharma LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions